Roche to present new data from its broad and innovative haematology portfolio at ASH 2025

Core Insights - Roche will present 46 abstracts, including 12 oral presentations, at the 67th American Society of Hematology (ASH) Annual Meeting from December 6-9, 2025, showcasing advancements in its hematology portfolio [1][2] Group 1: Key Presentations and Findings - The data presented at ASH highlight Roche's commitment to innovation in hematology and progress in treating blood disorders, particularly in hemophilia A, lymphoma, and multiple myeloma [2][5] - Key presentations include findings on cevostamab for relapsed/refractory multiple myeloma, demonstrating high overall response rates (ORR) and durable remissions [4][9] - New data from the Beyond ABR study on Hemlibra® (emicizumab) show low bleeding rates and improved joint health in patients switching from factor VIII prophylaxis [6][11] Group 2: Pipeline Developments - NXT007, a next-generation bispecific antibody, shows promise in normalizing hemostasis in hemophilia A and is set to enter phase III clinical development in 2026 [6][14] - SPK-8011QQ, an investigational AAV gene therapy, demonstrates enhanced hemostatic potency compared to its predecessor, with a phase IIb study planned for 2026 [6][15] - Lunsumio® (mosunetuzumab) shows potential as an effective outpatient treatment for relapsed/refractory follicular lymphoma, with positive preliminary data from ongoing studies [6][12] Group 3: Clinical Outcomes and Patient Benefits - Long-term follow-up data indicate sustained clinical benefits and improved quality of life for patients treated with Lunsumio plus Polivy® (polatuzumab vedotin) [6][13] - Columvi® (glofitamab) continues to show superior survival outcomes in combination with gemcitabine and oxaliplatin for patients with relapsed/refractory diffuse large B-cell lymphoma [6][34] - The findings from various studies underscore Roche's ongoing efforts to redefine treatment standards and improve patient outcomes in hematology [5][18]